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A bs tr ac t
Background
Observational and epidemiologic data indicate that the use of aspirin reduces the 
risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome 
(hereditary nonpolyposis colon cancer) are not known. Resistant starch has been 
associated with an antineoplastic effect on the colon.
Methods
In a randomized, placebo-controlled trial, we used a two-by-two design to investi-
gate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), 
at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among 
persons with the Lynch syndrome.
Results
Among 1071 persons in 43 centers, 62 were ineligible to participate in the study, 72 did 
not enter the study, and 191 withdrew from the study. These three categories were 
equally distributed across the study groups. Over a mean period of 29 months 
(range, 7 to 74), colonic adenoma or carcinoma developed in 141 participants. Of 693 
participants randomly assigned to receive aspirin or placebo, neoplasia developed 
in 66 participants receiving aspirin (18.9%), as compared with 65 receiving placebo 
(19.0%) (relative risk, 1.0; 95% confidence interval [CI], 0.7 to 1.4). There were no 
significant differences between the two groups with respect to the development of 
advanced neoplasia (7.4% and 9.9%, respectively; P = 0.33). Among the 727 partici-
pants receiving resistant starch or placebo, neoplasia developed in 67 participants 
receiving starch (18.7%), as compared with 68 receiving placebo (18.4%) (relative risk, 
1.0; 95% CI, 0.7 to 1.4). Advanced adenomas and colorectal cancers were evenly 
distributed in the two groups. The prevalence of serious adverse events was low, 
and the events were evenly distributed.
Conclusions
The use of aspirin, resistant starch, or both for up to 4 years has no effect on the 
incidence of colorectal adenoma or carcinoma among carriers of the Lynch syndrome. 
(Current Controlled Trials number, ISRCTN59521990.)
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The regular use of aspirin or aspi-rin-like agents is associated with a moder-ate reduction in the risk of colonic polyps 
and colorectal cancer.1-4 Randomized trials of 
high-fiber diets have not shown a reduction in the 
risk of adenomas or colorectal cancer,5 but none 
have investigated the effects of resistant starch. 
There is epidemiologic evidence of a negative 
correlation between colon cancer and starch in-
take.6 Resistant starches escape digestion in the 
upper gut; colonic fermentation yields short-chain 
fatty acids, including butyrate, which has anti-
neoplastic properties.7 In carcinogen-treated rats, 
resistant starch reduces the development of in-
testinal tumors8,9 and the production of aberrant 
crypt foci,10 lowers mucosal DNA damage,11 and 
increases apoptosis of damaged cells.12 Converse-
ly, excess numbers of polyps in the small bowel 
develop in strain Apc1638N mice fed a diet con-
taining high amounts of resistant starch (200 g 
per kilogram).13
We conducted a trial of colorectal-cancer pre-
vention that focused on carriers of DNA mis-
match-repair gene defects. These abnormalities 
underlie the Lynch syndrome (hereditary non-
polyposis colon cancer), an autosomal dominant 
genetic defect that confers a predisposition to 
colorectal cancer. Up to 5% of colorectal cancers 
result from the Lynch syndrome, which is char-
acterized by microsatellite instability of tumors. 
Several organs are susceptible to cancer, includ-
ing the intestines, endometrium, and ovaries.14 
The Lynch syndrome probably represents a “model 
system” for one of six sporadic cancers featuring 
microsatellite instability due to somatic MLH1 si-
lencing.15 In patients with the Lynch syndrome, 
adenomas appear at a mean age of 42.5 years, 
and the first diagnosis of colorectal cancer oc-
curs at a mean age of about 45 years. The risk of 
colon cancer among mutation carriers is 10% over 
a period of 10 years. In one study, colonic neo-
plasia had developed in 70.3% of carriers by 60 
years of age.16
We describe a randomized trial of chemopre-
vention with the use of 600 mg of aspirin, 30 g of 
resistant starch, or both daily for up to 4 years in 
patients with the Lynch syndrome.
ME THODS
In this two-by-two factorial, randomized, double-
blind, placebo-controlled trial, we tested whether 
the use of enteric-coated aspirin at a dose of 600 
mg per day, resistant starch at a dose of 30 g per 
day, or both prevents the development of colonic 
adenomas or colorectal cancer in patients with 
the Lynch syndrome. In this study, we used the 
collective term “neoplasia” to refer to colonic ad-
enomas and colorectal cancer; although the term 
was used in the general sense of “new growth,” 
it did not include presumably benign hyperplas-
tic polyps. Initially, participants were enrolled 
for 2 years. In 2001, an approved protocol amend-
ment allowed participants to be invited, immedi-
ately before the 2-year date, to continue in the 
trial for 2 more years.
The study was designed by members of the 
international steering committee of the Colorec-
tal Adenoma/Carcinoma Prevention Programme 2 
(CAPP2). The data were gathered and analyzed by 
the CAPP2 investigators. During the trial and be-
fore publication, except as noted below, data were 
kept confidential from the sponsors, institutions, 
and all study organizers except for two of the 
authors and the data and safety monitoring com-
mittee. Bayer and National Starch and Chemical 
provided the study agents free of charge, includ-
ing the cost of packaging, and they made dona-
tions to Newcastle University to help cover the 
cost of administration and distribution. They had 
no influence on the study design, conduct, or 
analysis or on preparation of the manuscript. 
The contracts associated with their donations re-
quired that the sponsors be given the right to 
review the results before submission of the man-
uscript, with up to 90 days for evaluation.
All relevant research ethics committees ap-
proved the study. Approval included the addition 
of an undeclared inert starch-compliance bio-
marker, 4-aminobenzoic acid (in Denmark, the 
addition of this biomarker was revealed). All 
participants gave written informed consent for 
participation in the study, including explicit 
consent for the provision of blood and tissue 
samples.
Patients
Eligible patients were older than 25 years of age 
and were proven carriers of a pathologic mis-
match-repair mutation (“genetic diagnosis”) or 
members of a family that met the Amsterdam 
diagnostic criteria and had a personal history of 
a cured Lynch syndrome neoplasm but an intact 
colon (“clinical diagnosis”). Colonoscopic exam-
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ination and clearance of polyps within 3 months 
after recruitment were prerequisites. Exclusion 
criteria were pregnancy, contraindications for the 
use of aspirin, the use of antiinflammatory agents, 
and severe intercurrent disease. Patients with re-
cent bowel cancer were excluded for 1 year if the 
pathological findings were consistent with Dukes’ 
stage A, for 2 years if they were consistent with 
Dukes’ stage B, and for 5 years if they were con-
sistent with Dukes’ stage C or D. If a partial 
colectomy had been performed, a daily bowel 
movement of three or fewer formed stools was 
required.
Study Design
The protocol specified a colonoscopic examina-
tion at study entry and an exit colonoscopic ex-
amination after 2 years of the study intervention, 
along with routine surveillance. Copies of histo-
logic reports plus pathological samples were re-
quested for independent pathological review.
Participants were randomly assigned separate-
ly for the two interventions (either assignment to 
aspirin or placebo or assignment to resistant 
starch or placebo), and half the participants were 
randomly assigned to receive either the active 
agent or placebo for each intervention. This ran-
domization should have resulted in four groups 
of equal size for assignments to aspirin plus 
placebo, aspirin plus starch, starch plus placebo, 
and placebo plus placebo. For some persons, 
however, randomization to one intervention was 
precluded by a factor such as sensitivity to aspi-
rin, and in such cases, randomization to the 
other intervention was permitted; this resulted in 
four additional (smaller) groups. For the main 
analysis, the two interventions were analyzed 
separately (e.g., participants who were randomly 
assigned to receive aspirin were compared with 
participants who were randomly assigned to re-
ceive aspirin plus placebo, regardless of whether 
they received resistant starch or placebo starch). 
Only the interaction analysis excluded partici-
pants who were randomly assigned to receive a 
single agent.
Randomization was computer-generated. The 
study centers were categorized into six geograph-
ic groups — Americas, southern Europe (the 
Iberian Peninsula and Italy), northern Europe, 
South Africa, the United Kingdom, and the 
Pacific Rim (Australia and Hong Kong). Block 
randomization (in blocks of 16) was performed 
separately for each group of centers to ensure 
balance across the four main study groups.
Study Regimens
The daily regimen consisted of 30 g of resistant 
starch (Novelose, National Starch and Chemical) 
or placebo cornstarch (with recommended admin-
istration in two separate doses) or two enteric-
coated aspirin tablets plus placebo or aspirin plus 
resistant starch. The test starch was a 1:1 blend 
of Novelose 240 and Novelose 330. Novelose 240, 
based on a corn (maize) hybrid containing 70% 
amylose and 30% amylopectin, is a granular 
source of resistant starch; Novelose 330 is simi-
lar but nongranular. The estimated dose of resis-
tant starch was 13.2 g (habitual intake in Europe 
was estimated to be 4.1 g per day)17; a daily dose 
of 28 g of resistant starch was found by others to 
cause considerable bloating. The resistant-starch 
control was waxy starch (Amioca) containing 
only amylopectin, a highly branched high-molec-
ular-weight polymer of α1,4-linked glucose with 
negligible resistant starch. The compliance bio-
marker used to assess compliance with the starch 
regimen was 4-aminobenzoic acid at a level of 
50 mg per day.
For aspirin, we used an enteric-coated tablet 
(Bayer) that contained 300 mg of acetylsalicylic 
acid. The aspirin placebo contained 36 mg of cal-
cium hydrogen phosphate, a trivial dietary dose.
The investigators and patients were unaware 
of the study-group assignments. Dispensing and 
related records were managed by the Newcastle 
Hospitals NHS Foundation Trust Pharmacy. After 
colonoscopic examination at study entry, packs 
containing the study drugs were sent directly to 
the participants or local clinicians and thereafter 
were sent every 6 months, when compliance data 
were collected.
Statistical Analysis
Descriptive statistics were used for study vari-
ables (including age, sex, eligibility status, and 
months in the study), with frequency tabulations 
for categorical variables and summary statistics 
(mean and range) for continuously distributed 
variables.
Participants who underwent a follow-up colon-
oscopic examination were included in the analy-
ses of treatment effects. The primary outcome 
was detection of at least one adenoma or colo-
rectal carcinoma at follow-up; since intervals be-
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tween colonoscopic examinations and the dura-
tion of participation in the study varied, the 
analysis considered time in the study in its en-
tirety. Secondary outcomes were the detection of 
an adenoma only, colorectal cancer only, adeno-
ma and colorectal cancer, and advanced adenoma 
or colorectal cancer. A neoplasm was classified 
as an advanced adenoma on the basis of one or 
more of the following features: a diameter of 1 cm 
or more, a villous or tubulovillous component, 
or high-grade dysplasia. Other secondary out-
comes were the neoplastic burden, defined as 
the sum of the maximum diameters of neo-
plasms detected by means of endoscopic exami-
nation during the study, and other cancers associ-
ated with the Lynch syndrome.
The primary analysis compared the occur-
rence of each outcome involving a neoplasm ac-
cording to whether the subject received resistant 
starch or aspirin. Secondary analyses were ad-
Table 1. Characteristics of the Participants.
Variable
Participants Recruited 
and Given Study Drug  
(N = 937)
Participants Included  
in Outcome Analysis  
(N = 746)
Participants Not 
Included in Outcome 
Analysis (N = 191) P Value*
Age at study entry — yr 0.63
Mean 45 46 46
Range 25–79 25–79 25–67
Sex — no. (%) 0.19
Female 525 (56.0) 410 (55.0)  76 (39.8)
Male 412 (44.0) 336 (45.0) 115 (60.2)
Geographic region — no. (%) 0.07
Northern Europe 423 (45.1) 334 (44.8)  89 (46.6)
United Kingdom 277 (29.6) 218 (29.2)  59 (30.9)
Australia and Hong Kong 133 (14.2) 116 (15.6) 17 (8.9)
Southern Europe 56 (6.0) 46 (6.2) 10 (5.2)
South Africa 44 (4.7) 29 (3.9) 15 (7.9)
Americas  4 (0.4)  3 (0.4)  1 (0.5)
Eligibility status — no. (%) 0.63
Clinical diagnosis 163 (17.4) 132 (17.7)  31 (16.2)
Genetic diagnosis 774 (82.6) 614 (82.3) 160 (83.8)
 Mutation — no./total no. (%) 0.18
MLH1 464/774 (60.0) 358/614 (58.3) 106/160 (66.3)
MSH2 284/774 (36.7) 235/614 (38.3)  49/160 (30.6)
MSH6 26/774 (3.4) 21/614 (3.4)  5/160 (3.1)
Time in study — mo
Mean 29.0
Range 7–74
Duration of receipt of study drug — mo
Mean 26.5
Range 1–67
No. of colonoscopic examinations
Mean 2.6
Range 2–7
* The P values are for the comparisons of patients who were included in the analysis with the patients who were not included.
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justed for age and sex. Adjustment for the pres-
ence or absence of bowel neoplasms before 
participation in the study, the number of colono-
scopic examinations, or both with the use of 
generalized linear models gave results that were 
equivalent to those seen after adjustment for age 
and sex only; these results are not reported. 
Time-to-event analysis was used in the second-
ary analysis, with the number of months to de-
tection of any neoplasia or an advanced adenoma 
or colorectal cancer as end points. Cox propor-
tional-hazards models adjusted for age and sex 
were used for treatment effects and Kaplan–
Meier survival curves.
Pearson’s chi-square test was used for analy-
ses of reasons for withdrawal from the study and 
serious adverse events as defined in the trial (pep-
tic ulcer, cerebrovascular incident, cardiovascular 
incident, deep venous thrombosis, cancer not as-
sociated with the Lynch syndrome, cancer other 
than colorectal cancer associated with the Lynch 
syndrome, other major events, and other minor 
events, including bleeding). Analyses included all 
events that occurred after study entry.
We anticipated that at least one adenoma 
would develop over a period of 2 years in 10% of 
the patients in the placebo group18; assuming a 
20% dropout rate, we calculated that a sample of 
1200 participants followed for 2 years would 
provide 90% power at a significance level of 0.05, 
based on a treatment effect of a 40% reduction 
in risk. The study had 73% power to detect a 50% 
reduction in the risk of an advanced adenoma or 
carcinomas.
Since there were fewer eligible gene carriers 
than predicted, an early approved protocol amend-
ment allowed participants to remain in the study 
longer; this reduced the target recruitment to 
1000 persons, assuming that 20% of participants 
would withdraw from the study and that 20% 
would continue for 2 more years. This amendment 
also stated that all participants would be included 
in the analysis, provided that there was a colono-
scopic examination at both study entry and study 
exit and regardless of the time in the study.
R ESULT S
Characteristics of the Patients
We recruited 1009 eligible patients. The analysis 
excluded 263 participants (26%); 72 withdrew 
before the colonoscopic examination at study en-
try, and 191 withdrew before the follow-up colono-
scopic examination. The remaining 746 partici-
pants were included in the analysis. There were 
no notable differences between the patients who 
were recruited and those who completed the 
study.
Table 1 and Table 1 in the Supplementary Ap-
pendix (available with the full text of this article 
at www.nejm.org) show the characteristics of the 
participants; at recruitment, 83% had a genetic 
diagnosis, and 17% had a clinical diagnosis. Sub-
sequently, a mismatch-repair mutation was dis-
covered in 49 of 163 patients who had a clinical 
diagnosis, but the original status was retained for 
the analysis. A total of 464 participants with a 
genetic diagnosis had a pathologic mutation in 
MLH1, 284 had a mutation in MSH2, and 26 had 
a mutation in MSH6. A total of 152 Finnish par-
ticipants had an MLH1 exon 16 deletion, and 35 
South African participants had a C1528T MLH1 
mutation. For at least 80% of the time, 81% of 
participants complied with the use of aspirin and 
77% of the participants complied with the use of 
resistant starch. A subgroup of 100 participants 
from the United Kingdom completed a 4-day 
dietary assessment and provided a urine sample; 
the compliance biomarker 4-aminobenzoic acid 
was detected in 93% of these participants.
The average duration of participation in the 
study was 29 months (range, 7 to 74); they re-
ceived the study drugs for 27 months (Table 1) 
and underwent an average of 3 colonoscopic ex-
aminations (range, 2 to 7, including the exami-
nation at study entry). There was even distribu-
tion among study groups (Table 2) with regard 
to total years of follow-up, the mean age of the 
participants, and the number of colonoscopic 
examinations. Table 2 includes data on partici-
pants who were randomly assigned to receive one 
agent only. A central histologic review of all of 
the available tumor tissue obtained from 132 of 
197 persons (67.0%) was performed. There was 
93% agreement between local and central re-
views of detected neoplasia and 79% agreement 
for classification of nonadvanced and advanced 
neoplasia. Discordant opinions were reviewed by 
the study team, and the opinion of the reviewers 
at the central site was preferred if it was clear 
that both pathologists had examined the same 
tissue.
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Table 2. Distribution of Characteristics According to Study Group.
Variable
All Participants  
Recruited
(N = 937) Participants Assigned to Both Interventions
Aspirin plus 
Resistant Starch  
(N = 214)
Aspirin plus  
Placebo  
(N = 204)
Resistant Starch 
plus Placebo  
(N = 208)
Placebo  
plus Placebo  
(N = 216)
Withdrawal from study — no. (%) 191 (20.4)  39 (18.2)  38 (18.6)  51 (24.5)  40 (18.5)
Inclusion in analysis — no. (%) 746 (79.6) 175 (81.8) 166 (81.4) 157 (75.5) 176 (81.5)
 Age — yr
Mean 44 43 43 44
Range 24–8 21–68 24–75 25–77
Sex — no./total no. (%)
Female 410/746 (55.0)  94/175 (53.7) 103/166 (62.0)  80/157 (51.0)  96/176 (54.5)
Male 336/746 (45.0)  81/175 (46.3)  63/166 (38.0)  77/157 (49.0)  80/176 (45.4)
Diagnosis — no./total no. (%)
Clinical 132/746 (17.7)  21/175 (12.0)  29/166 (17.5)  33/157 (21.0)  31/176 (17.6)
Genetic 614/746 (82.3) 154/175 (88.0) 137/166 (82.5) 124/157 (79.0) 145/176 (82.4)
 Neoplasia before study entry — no./total no.  
with full, available medical records (%)
No 231/525 (44.0)  57/128 (44.5)  55/108 (50.9)  48/114 (42.1)  57/123 (46.3)
Yes 294/525 (56.0)  71/128 (55.5)  53/109 (49.1)  66/114 (57.9)  66/123 (53.7)
 Neoplasia at colonoscopic examination  
at study entry — no./total no. (%)
No 641/746 (85.9) 155/175 (88.6) 140/166 (84.3) 134/157 (85.4) 154/176 (87.5)
Yes 105/746 (14.1)  20/175 (11.4)  26/166 (15.7)  23/157 (14.6)  22/176 (12.5)
Advanced adenoma at colonoscopic 
 examination at study entry — 
no./total no. (%)
35/746 (4.7)  9/175 (5.1)  6/166 (3.6)  9/157 (5.7)  8/176 (4.5)
No. of adenomas — no./total no. (%)
1  88/105 (83.8) 16 23 18 18
2  13/105 (12.4)  4  2  3  3
3  3/105 (2.9)  0  0  2  1
4 0/105  0  0  0  0
5  1/105 (0.9)  0  1  0  0
Total 105/105 (100) 20 26 23 22
No. of colonoscopic examinations
Mean 2.6 2.6 2.7 2.7
Range 2–7 2–6 2–6 2–5
 Follow-up — yr
Total person-years of follow-up 415 393 390 434
Mean 2.4 2.4 2.5 2.5
Range 0.8–4.7 0.7–4.5 0.9–6.2 0.9–4.9
Compliance
Mean proportion of unused aspirin tablets 0.11 0.09 0.11 0.13
Mean proportion of unused starch sachets 0.14 0.10 0.16 0.14
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Outcomes
A bowel neoplasm was identified in 141 partici-
pants (18.9%), reflecting 90% power to detect a 
40% difference in risk, as anticipated. Isolated 
colorectal cancer occurred in 13 participants, a 
combination of colorectal cancer and adenomas 
in 10, and adenomas only in the remaining 118. 
Numbers and mean diameters of the neoplasms 
are listed in Table 3. Table 4 shows the compari-
son for the two study agents separately; of 693 
participants who were randomly assigned to re-
ceive aspirin or placebo, 66 of 349 (18.9%) had one 
or more neoplastic lesions while receiving aspi-
rin, as compared with 65 of 342 in the placebo 
group (19.0%). Overall, the crude relative risk for 
the development of neoplasms in the aspirin group 
was 1.0 (95% confidence interval [CI], 0.7 to 1.4). 
After adjustment for age at enrollment, sex, and 
the number of colonoscopic examinations, there 
was no statistical evidence of a difference be-
tween the active-treatment and placebo groups. 
The analyses of adenomas only, colorectal cancer 
only, and adenomas and colorectal cancer showed 
no significant differences among the study groups. 
There was no evidence of an interaction between 
study agents (P = 0.98).
The incidence of advanced adenoma or colo-
rectal cancer, a measure of overt cancer plus 
adenomas thought to have the highest malig-
nant potential, was 8.4% in the aspirin group 
and 10.9% in the placebo group (P = 0.3). Of the 
727 participants who were randomly assigned to 
receive resistant starch or placebo, 67 of those 
in the resistant-starch group (18.7%) were found 
to have neoplasia, as compared with 68 in the 
placebo group (18.4%), corresponding to a crude 
odds ratio of 1.0 (95% CI, 0.7 to 1.4). Adenomas 
and colorectal cancers were distributed evenly 
between the two groups (Table 4).
Colorectal cancer developed in equal numbers 
of patients (10) in the aspirin and placebo groups 
(Table 2 in the Supplementary Appendix). In the 
aspirin group, colorectal cancer with or without 
additional adenomas developed in 20 partici-
pants, 10 of whom were receiving active treat-
ment and 10 of whom were receiving placebo. In 
the resistant-starch group, colorectal cancer with 
or without additional adenomas developed in 22 
participants, 10 of whom were receiving active 
treatment and 12 of whom were receiving place-
bo. A Lynch syndrome cancer (excluding colorec-
tal cancer) developed in 7 participants who re-
Participants Assigned to a Single Intervention
Aspirin  
Only  
(N = 9)
Placebo  
Only  
(N = 10)
Resistant Starch  
Only  
(N = 41)
Placebo  
Only  
(N = 35)
0 0 15 (36.6)  8 (22.9)
9 (100) 10 (100) 26 (63.4) 27 (77.1)
59 47 54 57
36–71 32–56 27–78 40–74
4/9 (44.4) 4/10 (40.0) 14/26 (53.8) 15/27 (55.6)
5/9 (55.6) 6/10 (60.0) 12/26 (46.1) 12/27 (44.4)
2/9 (22.2) 1/10 (10.0)  9/26 (34.6)  6/27 (22.2)
7/9 (77.8) 9/10 (90.0) 17/26 (65.4) 21/27 (77.8)
3/7 (42.9)  2/7 (28.6)  3/19 (15.8)  6/19 (31.6)
4/7 (57.1)  5/7 (71.4) 16/19 (84.2) 13/19 (68.4)
7/9 (77.8) 8/10 (80.0) 21/26 (80.8) 22/27 (81.5)
2/9 (22.2) 2/10 (20.0)  5/26 (19.2)  5/27 (18.5)
0/9 0/10 2/26 (7.7) 1/27 (3.7)
2 2 4 5
0 0 1 0
0 0 0 0
0 0 0 0
0 0 0 0
2 2 5 5
2 2.7 2.7 2.8
2–2 2–5 2–5 2–5
17 27 63 65
1.9 2.7 2.4 2.4
1.6–2.1 1.9–4.6 0.6–4.3 1.0–4.8
— — — —
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ceived resistant starch, as compared with 17 who 
received placebo (P = 0.05).
To test the influence of treatment duration on 
outcomes,19 we examined the incidence of neo-
plasia according to the number of years in the 
study. Hazard ratios (and 95% confidence inter-
vals) for all bowel neoplasms and advanced neo-
plasms revealed no evidence of a greater benefit 
with a longer duration of treatment (Fig. 1A 
through 1D). The analysis of all pathology re-
ports in each of four 12-month periods, com-
mencing at 6 months, showed no trend for a 
benefit of resistant starch over time but showed 
a possible adverse trend for aspirin, with the rela-
tive risk of neoplasia increasing from 0.6 to 1.9. 
Small numbers meant that for each group the 
confidence interval included 1 (Table 5 in the 
Supplementary Appendix).
Adverse Events
Table 3 in the Supplementary Appendix lists 
reasons for withdrawal from the study. Serious 
adverse events (Table 4 in the Supplementary 
Appendix) were infrequent and did not differ sig-
nificantly between groups. A total of 11 patients 
who received aspirin had gastric ulcers or bleed-
ing versus 9 patients receiving placebo, 2 receiv-
ing aspirin had cerebrovascular events versus 
3 receiving placebo, and 1 receiving aspirin had 
a cardiovascular event versus 5 among those re-
ceiving placebo.
DISCUSSION
We found that neither aspirin (at a dose of 600 
mg per day) nor resistant starch (Novelose) (at a 
dose of 30 g per day), alone or in combination, 
given for up to 4 years has any detectable effect 
on the incidence of intestinal neoplasms among 
adults with the Lynch syndrome. Furthermore, 
the 40% reduction in neoplasms postulated for 
aspirin lies at the extreme limit of possible ef-
fects, as evidenced by the confidence interval. 
The lack of effect of aspirin, despite evidence of a 
Table 3. Outcomes According to Study Group.
Variable All Participants Participants Assigned to Both Interventions
Participants Assigned to a Single 
Intervention
No. (%)
Aspirin 
plus
Resistant 
Starch
Aspirin 
plus
Placebo
Resistant 
Starch  
plus
Placebo
Placebo 
plus
Placebo
Aspirin
Only
Placebo
Only
Resistant 
Starch 
Only
Placebo 
Only
No neoplasia  — no./total no. (%) 605/746 (81.1) 142 137 127 143 5 8 22 21
Neoplasia — no./total no. (%) 141/746 (18.9) 33 29 30 33 4 2 4 6
Adenoma only 118/746 (15.8) 29 24 24 29 3 2 4 3
Colorectal cancer only 13/746 (1.7) 2 2 4 3 1 0 0 1
Adenoma and colorectal cancer 10/746 (1.3) 2 3 2 1 0 0 0 2
Advanced adenoma or colo-
rectal cancer 
68/746 (9.1) 10 15 18 15 1 1 3 5
Largest dimension of neoplasm — mm         
Mean 137 8.0 10.3 10.8 8.3 2.9 8 11.5 13.0
Range 1–68 2–39 1–70 1–40 1–5 8–8 3–23 2–55
No. of adenomas — no/total no. (%)
1  97/128 (75.8) 24 21 19 23 3 1 3 3
2  20/128 (15.6) 5 4 3 5 0 1 0 2
3  6/128 (4.7) 1 1 3 1 0 0 0 0
4  2/128 (1.6) 1 0 0 1 0 0 0 0
5  3/128 (2.3) 0 1 1 0 0 0 1 0
Total 128/128 (100) 31 27 26 30 3 2 4 5
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benefit in sporadic colorectal cancer,1-3 may indi-
cate a distinct mismatch-repair–dependent neo-
plastic pathway that is less susceptible to protec-
tion by aspirin. An analysis of expression of 
cyclooxygenase-2 by Lynch syndrome tumors is 
under way to test the reported association with 
aspirin as a chemopreventive agent.20 In our trial, 
aspirin was administered at a dose of 600 mg 
daily. Baron et al.2 suggested that a daily dose of 
325 mg of aspirin is less effective than a daily 
dose of 81 mg, although epidemiologic studies 
provide support for a positive dose–response re-
lationship.
The lack of an effect suggests that a larger 
study is unlikely to result in a different conclu-
sion; more modest protective effects than the 
postulated 40% reduction in neoplasms are still 
consistent with our data but would require much 
larger samples to detect. The results of analyses 
restricted to proven mutation carriers were in-
distinguishable from the results presented here 
(data not shown). Polyps that were present but 
not detected at study entry could have weakened 
any effect, but a miss rate equivalent to that re-
ported by Pickhardt et al.21 would not have 
changed the results. Furthermore, the frequency 
of such omissions would probably have been 
similar among the study groups.
The U.S. Preventive Services Task Force22 rec-
ommended that aspirin not be used routinely for 
the prevention of primary colorectal cancer. Sub-
sequently, Flossmann and Rothwell19 reported 
longer-term effects of aspirin on the risk of 
death from cancer among British men in two 
early trials of the benefits of aspirin in cardio-
vascular and cerebrovascular disease. There were 
significantly fewer deaths from colorectal cancer 
among persons who received aspirin; however, 
this did not become apparent until 10 years after 
the trial commenced, even though the aspirin 
was given for only 4 years during the trial. Such 
an effect — through a later influence on the de-
velopment of adenomas, the precursors of colo-
rectal cancer — cannot be ruled out in the CAPP2 
Table 4. Comparison of Outcomes According to Study Agent.*
Variable
Aspirin 
(N = 350)
Placebo
(N = 343) P Value
Resistant Starch
(N = 358)
Placebo
(N = 369) P Value
Development of neoplasia — no. of patients (%)
No neoplasia 284 278 291 301
Neoplasia 66 (18.9) 65 (19.0) 0.96 67 (18.7) 68 (18.4) 0.99
Adenoma only 56 (16.0) 55 (16.0) 0.96 57 (15.9) 56 (15.2) 0.86
Colorectal cancer only 5 (1.4) 7 (2.0) 0.54 6 (1.7) 6 (1.6) 0.90
Adenoma and colorectal cancer 5 (1.4) 3 (0.9) 0.45 4 (1.1) 6 (1.6) 0.43
Advanced adenoma or colorectal cancer 26 (7.4) 34 (9.9) 0.33 31 (8.7) 35 (9.5) 0.61
Neoplastic burden — mm†
Mean 8.7 9.4 0.7 9.4 9.5 1.0‡
Range 0.4–68 1–70 1–70 1–55
No. of adenomas — no. of patients (%)
1 48 (13.7) 43 (12.5) 46 (12.8) 47 (12.7)
2 9 (2.6) 9 (2.6) 8 (2.2) 11 (3.0)
3 2 (0.6) 4 (1.2) 4 (1.1) 2 (0.5)
4 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3)
5 1 (0.3) 1 (0.3) 2 (0.6) 1 (0.3)
* P values were adjusted for age and sex.
† The neoplastic burden was estimated as the sum of the maximum diameters of lesions.
‡ The P value was calculated on the basis of the two-sided t-test.
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cohort and is supported by the reduced incidence 
of cancer among carriers of the Lynch syndrome 
gene who undergo removal of polyps at regular 
colonoscopic examinations.19
The limited preliminary evidence concerning 
resistant starch is insufficient to define the op-
timum dose, and the dose used in our study was 
based on earlier studies of biomarkers18 and 
tolerability. The dose we used was tolerable, but 
it was three times as high as the typical intake 
of resistant starch in Europe. The lack of effect 
may reflect an insufficient dose, a less-than-
ideal compliance rate (77%), or the fact that a 
benefit in laboratory animals does not always 
translate into a benefit for humans.
Our trial has shown the feasibility of per-
forming chemoprevention trials in a population of 
people with a genetic susceptibility. The results, 
however, do not show a clinical benefit among 
carriers of a mutation for the Lynch syndrome who 
receive aspirin or resistant starch for up to 4 years. 
Longer-term effects remain to be evaluated.
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Figure 1. Time to the Development of Neoplasia, According to Study Group.
Panel A shows the time to the development of an adenoma or colorectal cancer among patients who received aspi-
rin as compared with those who received placebo; the unadjusted hazard ratio was 1.1 (95% CI, 0.8 to 1.5; P = 0.69). 
When the data were adjusted for the number of colonoscopic examinations, the hazard ratio was 1.0 (95% CI, 0.7 to 
1.5; P = 0.79). Panel B shows these outcomes among patients who received resistant starch as compared with those 
who received placebo; the unadjusted hazard ratio was 1.0 (95% CI, 0.7 to 1.4; P = 0.94). When the data were adjust-
ed for the number of colonoscopic examinations, the hazard ratio was 1.0 (95% CI, 0.7 to 1.4; P = 0.98). Panel C 
shows the time to the development of advanced adenoma or colorectal cancer in the aspirin group as compared 
with the placebo group; the unadjusted hazard ratio was 0.9 (95% CI, 0.5 to 1.5; P = 0.71). When the data were ad-
justed for the number of colonoscopic examinations, the hazard ratio was 0.9 (95% CI, 0.5 to1.5; P = 0.67). Panel D 
shows these outcomes for the resistant-starch group as compared with the placebo group; the unadjusted hazard 
ratio was 0.8 (95% CI, 0.5 to 1.4; P = 0.50).
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